SavedAdd your journal

Journals / Toraks Dergisi / 2007 / Cilt: 8 - Sayı: 4

Evaluating subjective and objective criteria of acute bronchodilator response (with formoterol and ipratropium) in stable COPD patients

Stabil dönemdeki KOAH’lı hastalarda akut bronkodilatör cevabın (formeterol ve ipratropium bromür ile) subjektif ve objektif kriterlerle değerlendirilmesi

Tuba KARAKAYA
Berna Adile DURSUN
Nazire UÇAR
Sibel ALPAR
Bahar KURT
Durdu SERTKAYA
Pages
207–210
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It was concluded that an acute bronchodilator response in COPD can be detected by subjective and objective criteria.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The purpose of our study was to determine whether anticholinergic and long-acting β2 agonist drug - mediated acute bronchodilator response of stable COPD patients can be detected by subjective (Borg dyspnoea scale- BDS) and objective (pulmonary function test-PFT) findings.
📊
Key Findings & Data:BDS and PFTs were performed on 33 stable COPD patients before and after ipratropium bromide and formoterol medication.
💡
Conclusion & Impact:It was concluded that an acute bronchodilator response in COPD can be detected by subjective and objective criteria.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:İpratropyum · İlaçların fizyolojik etkileri · Solunum fonksiyon testleri

Abstract

The purpose of our study was to determine whether anticholinergic and long-acting β2 agonist drug - mediated acute bronchodilator response of stable COPD patients can be detected by subjective (Borg dyspnoea scale- BDS) and objective (pulmonary function test-PFT) findings. We also investigated the difference in acute bronchodilator response mediated by these two drugs. BDS and PFTs were performed on 33 stable COPD patients before and after ipratropium bromide and formoterol medication. The difference in the effectiveness of these two drugs was compared. The BDS and all PFT parameters differed significantly after ipratropium bromide. The BDS and the RV/TLC decreased and the other parameters increased. After formoterol, the PFT parameters ,except RV/TLC, increased and BDS decreased. While the Mean Inspiratory Capacity (IC) was 2167.88±731.63 (880-3460) ml. before medication, it increased to 2384.24±771.80 (1060-3650) ml. after ipratropium bromide. For formoterol, the Mean IC was 2107.58±738.39 (920-3490) ml. and 2311.82±759.24 (1060-3780) ml. before and after medication, respectively. Ipratropium bromide was found to be more potent in increasing IC than formoterol. No significant difference was found in terms of BDS and PFT parameters between the two drugs. It was concluded that an acute bronchodilator response in COPD can be detected by subjective and objective criteria. The increase in IC obtained by anticholinergic drugs is greater than that of a β2 agonist.

Özet

Çalışmamızın amacı stabil KOAH’lı hastalarda antikolinerjik (ipratropium bromür) ve uzun etkili β2 agonist (formeterol) ilaçlar ile oluşan akut bronkodilatör cevabın, subjektif (Borg dispne skalası) ve objektif bulgularla (solunum fonksiyon testleri, akciğer volümleri) belirlenip belirlenemeyeceğini ve iki ilaç arasında akut bronkodilatör cevap açısından farklılık olup olmadığını araştırmaktır. Stabil KOAH’lı, ek hastalığı olmayan 33 hastaya ipratropium bromür ve formeterolden önce ve sonra ayrı ayrı Borg dispne skalaları ve akciğer volümleri dahil solunum fonksiyon testleri (SFT) uygulandı. Dispnenin subjektif ve objektif olarak ilaç öncesi ve sonrası değerlendirmesi yapıldı. Ayrıca iki ilacın etkinlik farkının olup olmadığı araştırıldı. İpratropium bromür sonrası Borg dispne skalası ve tüm SFT parametreleri açısından anlamlı bir fark saptandı. Bu fark Borg dispne skalası ve Rezidüel Volüm/Total Akciğer Kapasitesi (RV/TAK) parametresinde azalma, diğer parametrelerde artma şeklindeydi. Formeterol sonrası ise RV/TAK hariç tüm SFT parametreleri açısından artma şeklinde, Borg dispne skalası açısından azalma şeklinde anlamlı bir fark saptandı. İpratropium bromür öncesi ortalama inspiratuar kapasite (İK) 2167.88±731.63 (880-3460) ml. iken, sonrasında 2384.24±771.80 (1060-3650) ml’ye, formeterol öncesi ise ortalama İK değeri 2107.58±738.79 (920-3490) ml. iken sonrasında 2311.82±759.24 (1060-3780) ml’ye yükseldi ve İK’deki artış açısından ipratropium bromür, formeterole göre daha etkin bulundu. Borg dispne skalası ve SFT parametreleri açısından iki ilaç arasında etkinlik farkı saptanmadı. KOAH’da akut bronkodilatör cevap, subjektif kriterlerle ve objektif kriterlerden FEV1’in yanı sıra İK ile de belirlenebileceği ve antikolinerjik ilaçların yaptığı İK artışının, uzun etkili β2 agonistlere göre daha fazla olduğu sonucuna varıldı.

🔖

Cite This Article

KARAKAYA, T., DURSUN, B. A., UÇAR, N., ALPAR, S., KURT, B., SERTKAYA, D. (2007). Evaluating subjective and objective criteria of acute bronchodilator response (with formoterol and ipratropium) in stable COPD patients. Toraks Dergisi, Cilt: 8 - Sayı: 4, 207–210. https://ajindex.com/articles/368059

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Kronik Obstrüktif Akciğer Hastalığına Karşı Küresel Girişim. KOAH’ın tanısı,tedavisi ve önlenmesi için küresel strateji NHLBI/WHO çalışma raporu 2001;2
  2. American Thoracic Society. Standarts for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med 1995; 152: 77-120
  3. Çavdar T, Ekim N, Umut S, Erdinç E. Kronik obstrüktif akciğer hastalığı. Toraks Kitapları, İstanbul 2000; 1-104
  4. Newton MF, O’Donnell DE, Forkert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hiperinflation. Chest 2002; 121: 1042-50
  5. O’Donnell DE, Forkert L, Webb KA. Evaluation of bronchodilator responses in patients with “irreversible” emphysema. Eur Respir J 2001; 18: 914-20
  6. Duranti R, Filippelli M, Bianchi R. Inspiratory capacity and decrease in lung hiperinflation with albuterol in COPD. Chest 2002; 122: 2009-14
  7. Pellegrino R, Rodarte JR, Brosasco V. Assesing the reversibility of airway obstruction. Chest 1998; 114: 1607-12
  8. Hadcroft J, Calverley A PM. Alternative methods for assesing bronchodilator reversibility in chronic obstructive pulmonary disease. Thorax 2001; 56: 713-20
  9. Boni E, Corda L, Franchini D. Volume effect and exertional dyspnoea after bronchodilator in patient with COPD with and without expiratory flow limitation at rest. Thorax 2002; 57: 528-32
  10. Di Marco F, Milic-Emili J, Boveri B et al. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir J 2003; 21: 86-94
  11. Murariu C, Ghezzo H, Milic-Emili J, Gautier H. Exercise limitation in obstructive lung disease. Chest 1998; 114: 965-8
  12. Marin JM, Carrizo SJ, Gascon M et al. Inspiratory capacity, dynamic hiperinflation, breathlessness and exercise performance during the 6-minute-walk test in COPD. Am J Respir Crit Care Med 2001; 163: 1395-9
  13. O’Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in COPD. Am J Respir Crit Care Med 1999; 160: 542-9
  14. Pellegrino R, Brusasco V. Lung hiperinflation and flow limitation in chronic airway obstruction. Eur Respir J 1997; 10: 543-9
  15. Celik G, Kayacan O, Beder S, Durmaz G. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo controlled comparison of onset and duration of action. Respiration 1999; 66: 434-9
  16. Diaz O, Villafranca C, Ghezzo H et al. Role of inspiratory capa